» Articles » PMID: 37371066

Fundamental Characterization of Antibody Fusion-Single-Chain TNF Recombinant Proteins Directed Against Costimulatory TNF Receptors Expressed by T-Lymphocytes

Abstract

The costimulatory signal regulated by the members of the tumor necrosis factor receptor (TNFR) superfamily expressed by T cells plays essential roles for T cell responses and has emerged as a promising target for cancer immunotherapy. However, it is unclear how the difference in TNFR costimulation contributes to T cell responses. In this study, to clarify the functional significance of four different TNFRs, OX40, 4-1BB, CD27 and GITR, we prepared corresponding single-chain TNF ligand proteins (scTNFLs) connected to IgG Fc domain with beneficial characteristics, i.e., Fc-scOX40L, Fc-sc4-1BBL, Fc-scCD27L (CD70) and Fc-scGITRL. Without intentional cross-linking, these soluble Fc-scTNFL proteins bound to corresponding TNFRs induced NF-kB signaling and promoted proliferative and cytokine responses in CD4 and CD8 T cells with different dose-dependencies in vitro. Mice injected with one of the Fc-scTNFL proteins displayed significantly augmented delayed-type hypersensitivity responses, showing in vivo activity. The results demonstrate that each individual Fc-scTNFL protein provides a critical costimulatory signal and exhibits quantitatively distinct activity toward T cells. Our findings provide important insights into the TNFR costimulation that would be valuable for investigators conducting basic research in cancer immunology and also have implications for T cell-mediated immune regulation by designer TNFL proteins.

Citing Articles

Generation and characterization of OX40-ligand fusion protein that agonizes OX40 on T-Lymphocytes.

Sato A, Nagai H, Suzuki A, Ito A, Matsuyama S, Shibui N Front Immunol. 2025; 15:1473815.

PMID: 39867912 PMC: 11757143. DOI: 10.3389/fimmu.2024.1473815.

References
1.
Aschmoneit N, Kocher K, Siegemund M, Lutz M, Kuhl L, Seifert O . Fc-based Duokines: dual-acting costimulatory molecules comprising TNFSF ligands in the single-chain format fused to a heterodimerizing Fc (scDk-Fc). Oncoimmunology. 2022; 11(1):2028961. PMC: 8786347. DOI: 10.1080/2162402X.2022.2028961. View

2.
Schmidts A, Ormhoj M, Choi B, Taylor A, Bouffard A, Scarfo I . Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma. Blood Adv. 2019; 3(21):3248-3260. PMC: 6855119. DOI: 10.1182/bloodadvances.2019000703. View

3.
Balmanoukian A, Infante J, Aljumaily R, Naing A, Chintakuntlawar A, Rizvi N . Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors. Clin Cancer Res. 2020; 26(23):6196-6203. DOI: 10.1158/1078-0432.CCR-20-0452. View

4.
Sugamura K, Ishii N, Weinberg A . Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. Nat Rev Immunol. 2004; 4(6):420-31. DOI: 10.1038/nri1371. View

5.
Guttman-Yassky E, Simpson E, Reich K, Kabashima K, Igawa K, Suzuki T . An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study. Lancet. 2022; 401(10372):204-214. DOI: 10.1016/S0140-6736(22)02037-2. View